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On-admission versus in-hospital thromboembolism due 
to COVID-19 infection. What is the particular characteristic 
of those with early thrombotic events?
Abstract
Introduction: Increasing evidence has declared a hypercoagulable state in the coronavirus 2019 infection (COVID-19), while the 
etiology has remained a question. For the first time, the current study has aimed to compare the contributors of thromboembolism 
among those whose primary manifestations of COVID-19 were thrombosis vs the patients with a thrombotic event during the 
period of hospitalization.
Material and methods: This case-control study has been conducted on 267 COVID-19 patients, including 59, 48, and 160 ones 
with an on-admission, in-hospital, and without a thrombotic event, respectively. The events were defined as deep vein thrombosis 
(DVT), ischemic cerebrovascular accidents (CVA), pulmonary thromboembolism (PTE), or acute myocardial infarction (AMI). The 
demographic, physical examination, clinical and laboratory assessments of the groups were compared.
Results: The DVT (OR: 5.18; 95% CI: 1.01–26.7), AMI (OR: 11.1; 95% CI: 2.36–52.3), and arterial thrombosis (OR: 5.93; 95% CI: 
0.63–55.8) were significantly associated with an on-admission thrombosis compared to those who presented in-hospital events. 
Lower levels of oxygen saturation were the only significant predictor index inversely associated with on-admission thrombosis 
compared to those with an event during the hospital admission period.
Conclusion: PTE development was the most common in-hospital thrombotic event, whereas other thromboembolism types were 
remarkably more often among cases with on-admission events. Oxygen saturation was the only predictor of premature thrombo-
sis that was inversely associated with outpatient events.
Key words: COVID-19, thrombophilia, thromboembolism, SARS-CoV-2, case-control studies 
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Introduction
The pandemic of the novel coronavirus in-
fection (COVID-19) is still progressing worldwide 
and is the underlying etiology of numerous daily 
deaths since December 2019 [1].  COVID-19 pre-
sentation varies from asymptomatic courses in 
30–40% of the cases. Of those symptomatic ones, 
81% experience a mild disease, 14% are moderate 
cases, and the remained 5% develop intense en-
dothelial activation with exuberant inflammatory 
response, a remarkable cytokine release associated 
with Acute Respiratory Distress Syndrome (ARDS) 
and multiple organ failure (MOF). The overall 
fatality of COVID-19 accounts for 2.3% [2, 3].
An increasing body of evidence declares 
that patients with COVID-19 are predisposed to 
venous and arterial thrombosis [4]. The mecha-
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nism by which the patients are at a hypercoagu-
lable state is not well-recognized; nevertheless, 
it may link to overactivation of neutrophil traps 
and platelets, proinflammatory cytokine release, 
endothelial dysfunction, and complement acti-
vation [5–7].
Due to an increasing trend in the number of 
confirmed cases with severe COVID-19, numerous 
reports have been emerged suggesting that the 
patients with severe courses of COVID-19, re-
quiring hospitalization, intensive care unit (ICU) 
admission, and in general, critically ill patients 
are at significantly increased risk of thrombotic 
events development [8, 9]. Nevertheless, a paucity 
of knowledge is available regarding thrombosis 
incidence among mild-to-moderate cases who 
have developed on-admission thrombosis [10]. 
Thromboprophylaxis is a debating issue 
among COVID-19 patients; however, inadequate 
evidence for anticoagulant agents’ routine use is 
available [11–13]. The current study aims to com-
pare the characteristics of the COVID-19 patients 
with thrombosis on admission, during the period 
of hospital admission and with no thrombotic 
event, to make a thorough vision of thrombopro-
phylaxis necessity in target populations. 
Material and methods
Study population
The current case-control study has been con-
ducted on 267 patients in three groups, including 
59 ones with an on-admission thrombotic event, 
48 ones with thrombosis during hospitalization, 
and 160 ones without any thromboembolism. 
This multicentric study has been performed 
among the patients admitted at Amin and Alz-
ahra Hospitals (affiliated at Isfahan University of 
Medical Sciences) due to SARS-CoV-2 from May 
to June 2020. 
This study met the Helsinki ethics declara-
tion criteria and was derived from the approved 
proposal by Isfahan University of Medical Sci-
ences Ethics Committed by code IR.MUI.MED.
REC.1399.692. Written consent was obtained from 
the patients if possible; or by their legal guardians.
The case groups were selected from the pa-
tients with any thrombotic event, including deep 
vein thrombosis (DVT), ischemic cerebrovascu-
lar accidents (CVA), pulmonary thromboembo-
lism (PTE), or myocardial infarction (MI) whose 
COVID-19 infection was approved by a positive 
polymerase chain reaction (PCR) test. The partic-
ipants who met the inclusion criteria entered into 
the study using convenience sampling. The cases 
were divided into two groups, including on-ad-
mission thromboembolism, defined as admission 
due to any of the above events or thrombosis 
incidence by the first two days of hospitalization; 
otherwise, assigned as those with thromboem-
bolism during the period of hospital admission. 
Similar criteria were adopted for the control 
group.
Pregnancy, immune deficiency, history of co-
agulopathies, and a thromboembolic event within 
a month before the hospitalization regardless of 
its type (DVT, PTE, CVA, or MI) were determined 
as the exclusion criteria.
Diagnosis of thrombotic events
Presentations compatible with Well’s criteria 
with a confirmatory Doppler ultrasonography 
were administered to make a DVT diagnosis [14]. 
Suspicion of PTE due to clinical manifestation 
was confirmed using computed tomographic 
pulmonary angiography (CTPA) [15]. Acute MI 
was defined as ST-segment elevation myocardial 
infarction (STEMI) or non-STEMI according to 
a typical chest pain plus a significant increase 
in highly-sensitive troponin as a sensitive and 
specific cardiac biomarker. ST-segment elevation 
in two or more electrocardiogram leads indicating 
the involvement of a particular epicardial territo-
ry or new-onset left bundle branch block (LBBB) 
was defined as STEMI; otherwise, non-STEMI. 
Hemiplegia, facial hemiparesis, or dysarthria with 
a CT scan compatible with an ischemic CVA were 
the CVA determinants.
The included patients received anti-COVID-19 
infection and anticoagulation therapies according 
to Iran’s national guidelines. 
Data collection
The demographic characteristics, including 
age, gender, smoking, comorbidities (diabetes 
mellitus (DM), chronic obstructive pulmonary 
disease (COPD), end-stage renal disease (ESRD), 
any malignancy, cerebrovascular accidents (CVA), 
ischemic heart disease (IHD), and history of PTE), 
smoking and medical history, were entered into 
the study checklist.
On admission, hemodynamic information 
(oxygen saturation, pulse rate, systolic and di-
astolic blood pressure, respiratory rate, and 
mobility) and laboratory assessments (complete 
blood count, albumin, ferritin, C-reactive protein 
(CRP), d-dimer, prothrombin time (PT), partial 
thromboplastin time (PTT), international normal-
ized ratio (INR), fibrinogen, troponin, and lactate 
dehydrogenase (LDH)) were recorded in the study 
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checklist as well. A reference laboratory did all 
the assessments to minimize the potential bias.
The course of disease severity was defined 
according to an on-admission level of oxygen 
saturation; therefore, oxygen saturation > 93%, 
90–93%, and < 90% were determined as mild, 
moderate, and severe diseases.   
Anticoagulation in the studied group was 
classified as no anticoagulant therapy, prophylac-
tic, intermediate dose, and therapeutic dose. The 
remedies were initiated before thrombosis inci-
dence. Prophylactic doses included 5000 IU sub-
cutaneous unfractionated heparin (UFH) (3 times 
a day) [for BMI > 40 kg/m2:7500 IU subcutaneous 
UFH (three times a day)] or 40 mg subcutaneous 
enoxaparin (once daily) (for BMI > 40 kg/m2:40 mg 
subcutaneous enoxaparin (twice daily)) was ad-
ministered. Intermediate doses included 7500 IU 
subcutaneous UFH (three times a day) or 60 mg 
subcutaneous enoxaparin (daily). The therapeutic 
doses were determined as 80 IU/kg UFH bolus 
infusion followed by 18 IU/kg/h UFH infusion or 
1 mg/kg subcutaneous enoxaparin (twice daily). 
The doses were defined according to national pro-
tocols. The anticoagulant-related adverse effects, 
including gastrointestinal (GI) bleeding, hemopty-
sis, hematuria, were recorded. The other probable 
side effects such as easy bruising, petechiae, or 
purpura were categorized as other. 
The latter outcomes were ICU admission 
requirement, discharge/death, and non-invasive 
ventilation (NIV)/ intubation.
Data analysis
The obtained data were entered into the Sta-
tistical Package for Social Sciences (SPSS; version 
22.0, SPSS Inc., Chicago, IL, USA). The descrip-
tive data were presented in mean, standard devi-
ation, median, range for the continuous variable, 
and frequency and percentages for categorical 
variables. Regarding the three separate primary 
case-control studies, we aimed to compare the 
groups in pairs (without thrombotic event group 
with thrombose on admission group; without 
thrombotic event group with thrombosis during 
hospital group, thrombosis during hospital with 
thrombose on admission group). As the sample 
size in the two groups was less than 100, the nor-
mality of the data was assessed using the Kolm-
ogorov-Smirnov and Shapiro-Wilk tests. Since the 
distribution of some variables was not normal, 
nonparametric tests were used. The chi-square 
test or Fisher’s exact test was utilized to compare 
the categorical variables between the groups. The 
continuous variables were compared using the 
Mann-Whitney U test. Binary logistic regression 
analysis was applied to estimate the odds ratio and 
determine the association between the assessed 
factors and thrombotic events in the crude and 
adjusted model. Logistic regression was separately 
constructed for each of the factors in the crude 
model, while all variables were entered together in 
the adjusted model. In addition, logistic regression 
models were verified in terms of goodness of fit by 
–2 log-likelihood. A p-value of less than 0.05 was 
considered as a significant level.
Results
The current study has been conducted on 
267 COVID-19 patients. In-hospital thromboem-
bolism was significantly more frequent in males 
than in controls (p = 0.006). Among the hemody-
namic parameters, oxygen saturation (p = 0.020) 
and respiratory rate (p = 0.021) were statistically 
different between those with thrombosis during 
the hospitalization period and the controls, but 
not the other groups. Mobility status was an-
other significant difference among the studied 
groups. The laboratory parameters assessments 
revealed a remarkable difference in neutrophil, 
lymphocyte, and platelet counts, albumin, fer-
ritin, d-dimer, INR, fibrinogen, troponin, and 
LDH levels. PTE incidence (p < 0.0001) was the 
primary type of event in those who experienced 
thromboembolism during hospitalization, where-
as AMI was statistically more frequent among 
those with on-admission thrombosis (p = 0.003). 
The severity of COVID-19, anticoagulation and 
respiratory aid type were remarkably associated 
with thrombosis incidence (p < 0.05) (Table 1).
The time assessments revealed significant 
correlations between symptom initiation to ad-
mission and thrombosis incidence, the period 
between hospitalization to ICU admission, and 
the period between hospitalization to discharge 
or death (p < 0.05) (Table  2).
DVT, MI, and arterial thrombosis were signifi-
cantly associated with on-admission thrombosis 
compared to those who presented any thrombotic 
event during hospitalization. Lower levels of oxy-
gen saturation were the only significant predictor 
index inversely associated with on-admission 
thrombosis compared to those with an event 
during the hospital admission period.
Discussion
Patients with COVID-19 infection are typi-
cally admitted to the hospital because of respi-
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0.1340.2610.69058.8 (17.8)63.2 (18.8)61.8 (17.8)   Age-year mean (SD)
0.006*0.1780.17584 (52.5)36 (75.0)37 (62.2)   Gender-male, n (%)
Comorbidities, n (%)
0.4840.7230.38337 (23.1)8 (18.2)15 ( 25.4)   Diabetes
0.1920.4530.3816 (3.8)0 (0)1 (1.7)   COPD
0.1740.2180.73913 (8.1)1 (2.3)2 (3.4)   ESRD
0.3010.1710.83310 (6.3)1 (2.3)1 (1.7)   Malignancy
0.6360.6080.9948 (5.0)3 (6.8)4 (6.8)   CVA
0.036*0.0960.64225 (15.6)13 (29.6)15 (25.4)   IHD
0.5990.4600.3861 (0.63)0 (0)1 (1.7)   PTE history
0.4520.5450.2731 (10.6)3 (6.8)8 (13.6)   Smoking, n (%)
Pre-hospitalization medication — n (%)
0.2170.039*0.578118 (73.8)31 (64.6)35 (59.3)   None
0.6000.019*0.18828 (17.5)10 (20.8)19 (32.2)   Aspirin
0.0670.001*0.2520 (0)1 (2.1)4 (6.8)   Clopidogrel
0.1120.5060.4863 (1.9)3 (6.3)2 (3.4)   Prophylaxis anticoagulant
0.3390.9300.3653 (1.9)0 (0)1 (1.7)   Anticoagulant therapy
On-admission clinical presentations
0.020*0.8000.62086.3 (8.1)80.9 (10.8)84.2 (10.8)   O2 saturation, mean (SD)
0.9500.1470.37692.6 (19.8)90.1 (15.2)95.3 (21.2)   Pulse rate, mean (SD)
0.6500.1160.41435 (21.9)12 (25.0)19 (32.2)   Pulse rate > 100, n (%)
0.6220.5700.851124 (20.6)125 (19.2)121.4 (18.1)   Systolic blood pressure mean (SD)
0.2690.7200.1984 (2.5)0 (0)2 (3.4)   Systolic blood pressure < 90 mm Hg, n (%)
0.2490.4640.98575.6 (14.4)78.3 (14.3)76.4 (12.7)   Diastolic blood pressure, mean (SD)
0.2150.2270.0665 (3.1)0 (0)4(6.8)   Diastolic blood pressure < 60 mm Hg, n (%)
0.021*0.8560.07823.7 (6.2)25.7 (5.4)23.3 (7.3)   Respiratory rate, n (%)
0.6300.002*0.042*83 (51.9)23 (47.9)17 (28.8)   RBR
0.0730.010*0.587101 (63.1)37 (77.1)48 (81.4)   CBR







   Neutrophil count,  median (IQR)



























   Platelet× 10^-3,  median (IQR)
0.008*0.002*0.1513.5 (3.1–3.9)3.1 (2.9–3.6)3.4 (3.0–3.5)   Albumin [g/dL],  median (IQR)























On admission, laboratory characteristics





















   PT [s], median (IQR)
0.4420.032*0.40731 (28–34)30 (28–35)29 (28–33)   PTT [s], median (IQR)







   Fibrinogen [mg/dL], median (IQR)







   LDH [IU/L], median (IQR)
Thrombosis type, n (%)
––< 0.0001*–43 (89.6)29 (49.2)   PTE
––0.182–2 (4.2)7 (11.8)   DVT
––0.003*–2 (4.2)15 (25.4)   MI
––0.126–0 (0)4 (6.8)   CVA
––0.377–1 (2.1)4 (6.8)   Arterial
Disease severity, n (%)
0.009*0.8100.022*99 (61.9)41 (85.4)37 (62.7)   Severe
34 (21.3)3 (6.3)14 (23.7)   Moderate
27 (16.9)4 (8.3)7 (13.6)   Mild
Anticoagulation before thrombosis incidence, n (%)
0.427< 0.0001*< 0.0001*30 (18.8)9 (18.8)53 (89.8)   None 
97 (60.6)24 (50.0)4 (6.8)   Prophylactic doses
11 (6.9)4 (8.3)0 (0)   Intermediate doses
22 (13.8)11 (22.9)2 (3.4)   Therapeutic doses
Side effects of Anticoagulants, n (%)
0.0690.6130.0758 (5.0)6 (12.5)2 (3.4)   GI-bleeding
0.1930.9000.2696 (3.4)4 (8.3)2 (3.4)   Hemoptysis
0.1120.2900.0513 (1.9)3 (6.3)0 (0)   Hematuria
0.010*0.2940.2692 (1.3)4 (8.3)2 (3.4)   Others
Hospitalization outcome, n (%)
0.2220.5080.12084 (52.5)30 (62.5)28 (47.5)   ICU admission
<0.0001*0.9980.004*19 (11.9)17 (35.4)7 (11.9)   NIV
0.8590.7900.71838 (23.8)12 (25.0)13 (22.0)   Intubation
0.3990.2160.804129 (80.6)36 (75.0)43 (72.9)   Discharge
31 (19.4)12 (25.0)16 (27.1)   Death
Chi2/exact test for categorical variable and Mann-Whitney U for a continuous variable were significant if p < 0.05
Table 1. cont. Demographic and clinical characteristic of the studied population
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ratory distress, coughing, shortness of breath, 
and fever. Nevertheless, an increased risk of 
thrombosis in numerous cases has been noted 
[16], particularly among critically ill patients 
[17]. Although numerous studies have notified 
the significance of anticoagulant prophylaxis 
or therapy for ill ICU-admitted and even, to 
lower extents, for hospital admitted patients 
with COVID-19 pneumonia, risk of thrombosis 
development due to COVID-19 infection among 
unadmitted, hospitalized due to thrombosis and 
the SARS-CoV-2-infected patients without pneu-
monia had been underestimated.  
To the best of our knowledge, no effort has 
been made to compare the patients with an 
event before hospital admission versus those 
who developed it in the hospital. Our study’s 
main scope was to make a thorough vision of 
thromboprophylaxis necessity in outpatients with 
mild-to-moderate COVID-19 infections. 
In the current 3-armed parallel case-control 
study, we observed that the patients with on-ad-
mission thrombosis were similar to the second 
group who developed thrombosis in the course 
of hospitalization, and to the control group who 
did not experience any event, in terms of de-
mographic, past medical history, smoking and 
pre-admission medications. These findings were 
consistent with most of the previous studies in 
the literature [18–20].
An ineffective role of antiplatelet therapy to 
prevent thrombosis, either by aspirin or clopi-
dogrel, was a noteworthy finding of our study. 
Accordingly, we do not recommend antiplatelet 
treatment initiation for outpatients to minimize 
the risk of thrombotic events; however, by risk 
assessment, those on the treatment with these 
agents should continue [21]. Nevertheless, the 
insights about the routine administration of 
antiplatelet agents to prevent COVID-19-related 
complications are different. On the one hand, 
some of the researchers favored antiplatelet 
agents, aspirin in particular, as they present ear-
ly antiplatelet therapy may be beneficial due to 
their inhibitory effects on platelet activation and 
neutrophil-to-platelet aggregation generation; the 
critical mechanisms for thrombosis formation 
[22, 23]. It should be noted that most of the stud-
ies recommending aspirin administration have 
targeted patients with cardiovascular disorders, 
not all types of thrombotic events. On the other 
hand, growing evidence suggests antiplatelet 
therapy’s inefficacy for the primary prevention 
of thrombosis. According to the guideline, these 
agents are recommended regardless of being in-
fected with SARS-CoV-2 to secondarily prevent 
the events such as AMI, stroke, and peripheral 
artery disease in intervened cases [21].
Among the on-admission hemodynamic pa-
rameters, oxygen saturation and mobility status 
were the only significant differences among the 
three studied groups. Oxygen saturation is a de-
terminant of disease severity. Thus those with 
a more severe course of COVID-19 had worse 

















0.5270.012*0.3127 (3–10)7.5 (7–14)7 (2–14)Symptom initiation 
to admission
——< 0.0001*—18.5 (12–24.5)7 (2–14)Symptom initiation 
to thrombosis 
incidence
——< 0.0001*—7 (4–11.5)0Admission 
to thrombosis 
incidence
0.1790.0510.007*2 (1–5)2.5 (1–6)1 (0–2.5)Hospital-to-ICU 
admission
0.027*0.0001*< 0.0001*10 (6–17)17 (12.5–21)8 (5–10)Admission 
to discharge
0.011*0.1150.022*16 (9–21)13 (8.5–20.5)6.5 (2–14)Admission to death
Chi2/exact test for categorical variable and Mann-Whitney U for a continuous variable were significant if p < 0.05
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Table 3. Factors associated with premature thrombosis
Odds ratio for premature thrombosis (95% CI)
Thrombotic events during hospitalization
Crude Adjusted
Age 0.99 (0.97–1.02) 1.01 (0.97–1.04)
Comorbidity
   0 1 1
   1 1.10 (0.46–2.61) 0.46 (0.12–1.47)
   2 2.03 (0.36–11.3) 1.79 (0.18–17.80)
   3 0.81 (0.10–6.16) 0.37 (0.019–5.35)
   4 No data No data
Thrombosis type
   PTE 1 1
   DVT 5.18 (1.01–26.7)* 3.59 (0.21–59.73)
   MI 11.1 (2.36–52.3)* 7.04 (0.95–52.04)
  CVA No data No data
  Arterial 5.93 (0.63–55.8)* 1.42 (0.88–23.2)
On admission clinical or laboratory presentations
   O2 sat < 90 0.28 (0.10–0.74)* 0.13 (0.017–1.04)
   Respiratory rate 0.94 (0.88–1.01) 0.94 (0.83–1.04)
   Lymphocyte count 1.00 (0.99–1.00) 0.99 (0.99–1.01)
   D-dimer [ng/mL] 1.00 (0.99–1.00) 1.00 (1.00–1.00)*
   CRP [mg/L] 0.99 (0.98–1.01) 1.00 (0.98–1.01)
   LDH [IU/L] 1.00 (0.99–1.00) 1.00 (0.99–1.01)
Comorbidity: 0 = none, 1, 2, 3 = have at least one, two, or three of underlying disease (DM, COPD, CVA, IHD). Logistic regression was used to estimate the Crude 
and Adjusted (all variables entered in the model) odds ratio. In the crude model, the goodness fit was good so that the -2 log Likelihood was above 62 for each variable 
separately. However, in the adjusted model, it was about 44.57; *p < 0.05
oxygenation status that leads to immobility, 
non-invasive or mechanical ventilation require-
ment, ICU admission, and therefore, were prone 
to venous thromboembolic events [24, 25]. 
Higher levels of absolute neutrophil count 
among those with on-admission thrombosis in 
comparison to the two other groups not only rein-
forced the theory about the rule of neutrophil hy-
peractivity and neutrophil traps in COVID-19-re-
lated hypercoagulability pathogenesis [26] but 
also ignites a hypothesis in terms of neutrophil 
count administration to make a decision for 
thromboprophylaxis administration in outpatient 
cases [27]. Because of the significance of neutro-
phil count,  Petito et al. have even marked it as 
a more vital predictor of thrombosis than platelet 
in COVID-19 [28]. Albumin, d-dimer, platelet, 
and FDP were the other on-admission laboratory 
parameters that differed between the patients 
with on-admission events and the controls but 
not with the second group. However, we have 
no appropriate scale to decide for thrombopro-
phylaxis in COVID-19. The similarity of these 
on-admission parameters regardless of the time of 
event among the cases with thrombosis versus the 
control group can help provide a comprehensive 
view in this term.
On the other hand, a hypothesis is ignited 
that an appropriate cumulative cut-off value 
for these parameters may appropriately stratify 
thrombosis risk. It is worth noting that d-dimer 
and FDP are well-known representatives of co-
agulopathy and thrombosis [29], and albumin is 
an acute phase reactant relating to the severity of 
an inflammatory process [30].  PTE was the most 
common type of in-hospital thrombotic event, 
while the other types were more prominent in 
the latter group. Forty-three cases developed PTE, 
while only 24 and 11 were under prophylactic and 
therapeutic doses of anticoagulants, respectively. 
In addition, most of the cases with in-hospital 
events had severe courses of the disease. Throm-
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boembolism in critically ill patients has been 
reported in numerous studies [31–33], while 
Mestre-Gómez et al. represented a considerable 
rate of venous thromboembolic events among 
non-critical cases [19]. Moreover, the incidence 
of thromboembolism under anticoagulation has 
been notified as well; findings that promote the 
theory about the routine therapeutic anticoagu-
lant therapy among hospital admitted patients in 
general and severe COVID-19 cases in particular 
[19, 34].
The evaluation of predictors for premature 
thromboembolism incidence versus in-hospi-
tal events revealed that DVT, AMI, and arterial 
thrombosis incidence were considerably more 
probable to occur than PTE. None of the demo-
graphic, laboratory and hemodynamic parameters 
other than oxygen saturation was associated 
with on-admission events. Decreased oxygen 
saturation was a predicting factor for in-hospital 
thromboembolism, which is discussed above as 
a factor associated with disease severity, mobility, 
and ICU admission; accounted as risks of throm-
bosis, particularly PTE. 
We observed a significant interval between 
the day of symptom initiation and thrombosis 
incidence among those with on-admission versus 
in-hospital events, reinforcing the logic for rou-
tine use of anticoagulant agents in outpatients to 
prevent further events. Most of the studies regard-
ing anticoagulation in outpatient cases have been 
conducted on hospital discharged subjects who 
continued their treatment rather than outpatients 
[35, 36]. However, promising outcomes have 
been achieved for those outpatients treated with 
anticoagulant agents; the etiology has not been 
well investigated yet. According to IMPROVEDD 
[37] or other validated scoring systems, some of 
the researchers believe that thromboembolism 
risk assessment is required, and only moder-
ate-to-high risk cases should be administered the 
agents [13]. In contrast, the others claimed that 
anticoagulation is required for inpatients only 
[38]. However, according to growing data about 
the increased risk of thrombotic events, the inci-
dence thereof in mild-to-moderate COVID-19 pa-
tients have weighed the theory over the routine 
use of anticoagulants for outpatients [39].   
Conclusion
Based on this study, significant differences 
were observed in clinical and laboratory pa-
rameters between the cases with and without 
thrombotic events, while the patients with on-ad-
mission or in-hospital events were not notably dif-
ferent. PTE development was the most common in 
hospital, whereas other thromboembolism types 
were remarkably more frequent among cases with 
on-admission events. Oxygen saturation was the 
only predictor of premature thrombosis that was 
inversely associated with outpatient events. To 
make a decision for routine anticoagulation for 
patients with mild-to-moderate COVID-19 infec-
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